AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 282 min read$REGN

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit after a Phase 3 clinical trial for a melanoma treatment failed, causing a $11B market cap wipeout. The lawsuit alleges Regeneron misled investors about the trial's prospects between August 2025 and May 2026. Investors with losses before the September 2026 deadline are urged to contact Hagens Berman.

Original reporting
prnewswire.com
Published Aug 28, 2026, 4:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 5:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline — source image
Source · prnewswire.com
Decision brief

The 30-second read

$REGNBearishHigh
01

Why it matters

The disclosure represents the first public report of both the trial failure and the ensuing litigation, creating a material negative catalyst for the stock.

02

Market read

The news drives a sharp downside for Regeneron and may spill over to the broader biotech sector.

03

What to watch

Potential insurance recoveries or settlement terms could mitigate the financial impact.

Relevance 9/10Novelty 9/10Timing: immediate

Background

Regeneron announced that its Phase 3 trial of fianlimab + Libtayo failed to meet its primary endpoint, prompting a securities class‑action lawsuit.

Company-level read

Ticker impact

$REGNBearishHigh confidence
Context

Regeneron filed a securities class action after its Phase 3 melanoma trial failed, causing an $11 billion market‑cap loss.

Expected impact

Further share price decline as investors reassess valuation and potential settlement exposure.

Evidence & confidence

The filing is the first public disclosure of the trial failure and legal action, a material event for a large‑cap biotech.

Market effects

Sector

Biotech sector may face heightened scrutiny on trial disclosures and increased volatility.

Regional

US markets likely to see broader sell‑off in pharma stocks.

Global

Global investors with exposure to Regeneron may adjust positions, affecting international biotech ETFs.

Counterpoint

What could challenge this read

If the trial failure is isolated, Regeneron's pipeline depth could support a rebound once the legal risk resolves.

Key entities

  • company
    Regeneron Pharmaceuticals, Inc.

    US‑listed biotech company (NASDAQ: REGN) subject of the trial failure and lawsuit.

  • law_firm
    Hagens Berman Sobol Shapiro LLP

    Plaintiff law firm filing the securities class action.

Read at source← All news

Related articles

AUG 27
$REGNMedAI 8/10

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

finance.yahoo.com2 min
AUG 27
$REGNHighAI 8/10

REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Regeneron securities between August 1, 2025, and May 15, 2026, claiming misleading statements about a Phase III study.

accessnewswire.com1 min
AUG 26
$REGNMedAI 8/10

Regeneron terminates mAb eye therapy trial amid safety concerns

Regeneron halted its Phase I/IIa TITAN trial for mAb therapy REGN7041 due to safety concerns, according to a filing and company statement. The trial, targeting noninfectious uveitis, enrolled only one patient. Regeneron cited an unfavorable risk-benefit assessment and noted the cause of the safety event remains unidentified.

bioxconomy.com2 min
AUG 25
$REGNMedAI 9/10

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals (REGN) faces a securities class action lawsuit over alleged misstatements regarding a Phase 3 clinical trial for a melanoma treatment. The trial's failure caused a $11 billion market cap wipeout, prompting the lawsuit. Investors who purchased shares between August 1, 2025, and May 15, 2026, are urged to contact the law firm Hagens Berman by September 14, 2026.

globenewswire.com3 min
AUG 23
$REGNHighAI 9/10

Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru, a first-in-class treatment for fibrodysplasia ossificans progressiva. The approval is based on positive Phase 3 trial results. Analysts discuss how this new drug may impact Regeneron's investment narrative, alongside existing key products like EYLEA HD and Dupixent. The company projects $19.4B revenue and $6.0B earnings by 2029, with optimistic analysts suggesting higher figures.

simplywall.st2 min
AUG 22
$REGNLow

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals (NASDAQ:REGN) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Regeneron securities between August 1, 2025, and May 15, 2026, claiming misleading statements about a Phase III study. Investors have until September 14, 2026, to request lead plaintiff status.

accessnewswire.com2 min